ETANA STRENGTHENS PATIENT TRUST, LOCALLY PRODUCED ENOXAPARIN SODIUM OFFICIALLY HALAL CERTIFIED

Jakarta, October 21, 2025 – PT Etana Biotechnologies Indonesia (Etana) reinforce its commitment to delivering high-quality, innovative, and halalcompliant ealth products. This commitment is realized through obtaining the halal certificate for its Enoxaparin Sodium product from the Assessment Institute for Foods, Drugs, and Cosmetics of the Indonesian Ulema Council (LPPOM MUI).

Enoxaparin Sodium is a Low Molecular Weight Heparin (LMWH) product used for the prevention and treatment of blood vessel blockage disorders due to thromboembolism, such as in patients with heart disease, post surgery conditions, r dialysis therapy. The product is locally developed and produced by Etana using sheep (ovine) sourced raw materials, making it an effective, safe, and halal anticoagulant solution.

Wuragil Kartika Sari, Marketing Manager of Etana's Therapeutic Business Unit, stated, "Halal assurance has now become an important and crucial factor, especially since the majority of Indonesian society is Muslim. We understand that even though anticoagulant products are life-saving, having a halal option will help patients receive good therapy while gaining peace of mind regarding their religious beliefs," said Wuragil.

Furthermore, Wuragil explained that the halal certification process by LPPOM MUI involved a thorough examination of the entire production chain, from raw materials to the final process, to ensure the absence of non-halal content or contamination at every stage. Etana's Enoxaparin Sodium is developed and produced locally, as a form of our commitment to delivering high-quality and guaranteed halal therapy. We hope this step will strengthen the trust and sense of security for patients and health workers without compromising the quality or effectiveness of the treatment," she added.

With the halal certification officially obtained since August 2025, Etana hopes that Enoxaparin Sodium can broaden patient access to halal anticoagulant therapy, while also being part of the effort to strengthen national pharmaceutical self-sufficiency.

This step is aligned with Etana's vision to deliver innovative biotechnology products capable of meeting the needs of the Indonesian population with international standards.

"Our hope is that Etana's Enoxaparin Sodium will not only be a safe and trusted choice for patients but also strengthen the national pharmaceutical industry to be sovereign and globally competitive," concluded Wuragil.

Enoxaparin Sodium is used to help prevent and treat blood clots in various medical conditions, including post-operative patients and patients with blood vessel blockage disorders due to thromboembolism. The product is also used in the hemodialysis (blood washing) process and as part of the treatment therapy for acute heart attacks along with thrombolytic and antiplatelet drugs.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.